New Radioisotope for Cancer Therapy: A new Collaboration to produce copper-67

SASKATOON – Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies.  This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers. Iotron Medical, a spin-out business […]   READ MORE

Storied Nuclear Manufacturer, Niagara Energy Products, joins the CNIC

TORONTO – August 24, 2021 – Niagara Energy Products (NEP), a leader in the field of manufacturing radiation shielded containment vessels for isotopes and nuclear contaminated waste, has joined the Canadian Nuclear Isotope Council (CNIC). NEP has a long and storied history in Canada, with three large manufacturing plants in Ontario, providing high-quality jobs in […]   READ MORE

New partnership advances medical isotope technology

McMaster University and Promation have signed a Memorandum of Understanding (MoU) to work together to bring a new medical isotope technology developed at McMaster to the marketplace. At the center of this collaboration is a new technology for producing lutetium-177 (Lu-177), an increasingly sought-after medical isotope. Clinical trials have shown that Lu-177-based drugs have tremendous […]   READ MORE

CNIC signs historic MOU to collaborate on the 11th International Conference on Isotopes

TORONTO – May 12 , 2021  –The Canadian Nuclear Isotope Council (CNIC)  and the Local Organizing Committee of the 11th International Conference on Isotopes (11ICI) have entered into a Memorandum of Understanding to co-promote and support the conference’s success in 2022. The 11ICI will be  hosted by Sylvia Fedoruk Canadian Centre for Nuclear Innovation in […]   READ MORE

BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific

(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company. Developed for the treatment of patients with hepatocellular carcinoma (HCC), TheraSphere treatment is comprised of millions […]   READ MORE